News Category: Earnings

Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results

– 3Q22 net sales of $130.7 million – Prescription Drug User Fee Act action date set for March 12, 2023   for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Nov. 2, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

– 2Q22 net sales of $134.6 million , a 17% increase over 2Q21 – NDA submitted for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Aug. 8, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022 .

Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

– 1Q22 net sales of $115.5 million , an 8% increase over 1Q21 – Reiterating FY22 net sales guidance of $510 to $560 million – FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022 SAN DIEGO –(BUSINESS WIRE)–May 4, 2022– Acadia

Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results

– 3Q21 net sales of $131.6 million , a 9% increase over 3Q20 – FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA SAN DIEGO –(BUSINESS WIRE)–Nov. 8, 2021– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third

Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results

– 2Q21 net sales of $115.2 million , a 5% increase over 2Q20 – Fiscal year 2021 revenue guidance reduced to $480 to $515 million   – Type A meeting held with FDA regarding DRP; Acadia will continue discussion with FDA in another meeting later this year SAN DIEGO –(BUSINESS WIRE)–Aug.

Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results

– 1Q21 net sales of $106.6 million , an 18% increase over 1Q20 – Reiterating FY21 net sales guidance of $510 to $550 million SAN DIEGO –(BUSINESS WIRE)–May 5, 2021– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021 .